Sumar Sponsorii manifestării - Medicina Modernă

62
EFFECTS OF FIVE YEAR ATORVASTATIN TREATMENT ON C-
REACTIVE PROTEIN IN A GROUP OF CARDIOVASCULAR
PATIENTS
Beatrice Giorgiana Barac 1 , Victor Dumitraşcu 1,2 ,
Anca-Alexandra Matusz 3 , Daliborca Cristina Vlad 4 , Sorin Barac 5
Rezumat. Scop: Evaluarea efectelor
antiinflamatorii ale atorvastatinei asupra proteinei C
reactive (CRP) într-un lot de pacienţi cu afecţiuni
cardiovasculare.
Material şi metodă: Într-un studiu prospectiv, 55
de pacienţi cardiovasculari (vârsta medie 48±6 ani) au
fost împărţiţi în două loturi. În primul lot (Grupul de
studiu) 33 de pacienţi au primit zilnic 20 mg
atorvastatină asociată cu medicaţia antihipertensivă şi
antianginoasă uzuală. În al doilea grup, 32 de pacienţi au
primit numai tratament cardiovascular. Valorile CRP şi
fracţiunile lipidice s-au monitorizat comparativ pe
perioada celor cinci ani de studiu.
Rezultate şi discuţii: În grupul de studiu, CRP a
scăzut de la 21 la 8.40 mg/dl, comparativ cu grupul de
control, în care CRP a scăzut de la 20 la 15.80 mg/dl.
Concluzii: Rezultatele acestui studiu evidenţiază
că o doză zilnică de 20 mg atorvastatină a scăzut
semnificativ valorile CRP pe perioada celor cinci ani de
studiu.
Cuvinte cheie: atorvastatină, proteina C
reactivă, patienţi cardiovasculari.
Abrevieri: CRP = Proteina C reactivă.
Introduction
C-reactive protein (CRP) is a marker of
systemic inflammation and an indicator of high
risk for vascular events in cardiovascular patients
(1). It is already known that the goal of atorvastatin
treatment is to achieve the reduction in
cardiovascular events by the fall of LDL-C levels
(2). The aim of our study was to evaluate the antiinflammatory
effects of atorvastatin on CRP levels
in a group of cardiovascular patients.
Material and Methods
In a prospective study, 55 cardiovascular patients
Abstract. Objective: To evaluate the anti-inflammatory
effects of atorvastatin on C-reactive protein (CRP) levels
in a group of patients with cardiovascular diseases.
Material and Methods: In a prospective study 55
cardiovascular patients (mean age 48±6 years) were
divided into two groups. In the first group (Study
Group), 33 patients received 20 mg atorvastatin daily in
addition to their required antihypertensive and
antianginal treatment. In the second group (Control
Group), 32 patients received only the usual
cardiovascular treatment. CRP levels and lipid fractions
were monitored comparatively during the five year study
period.
Results and Discussion: In the study group, CRP
decreased from 21 to 8.40 mg/dl comparatively to the
control group where CRP decreased from 20 to 15.8
mg/dl.
Conclusion: The results of this study reveal that a
daily dose of 20 mg atorvastatin significantly decreased
CRP levels during a five-year follow-up survey.
Keywords: atorvastatin, C-reactive protein,
cardiovascular patients.
Abbreviations: CRP = C-reactive protein.
(mean age 48±6 years) were divided into two
groups. In the first group (Study Group), 33
patients received 20 mg atorvastatin daily in
addition to their required antihypertensive and
antianginal treatment. In the second group (Control
Group), 32 patients received only the usual
cardiovascular treatment. Baseline blood samples
were collected from patients for the measurement
of CRP, low-density lipoprotein cholesterol (LDL-
C) and high-density lipoprotein cholesterol (HDL-
C); the same tests were performed after 1 year and
4 years
1 Department of Pharmacology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 2 Emergency
Clinical County Hospital, Laboratory Department, Timisoara, Romania, 3 Family Healthcare Unit, Timisoara, Romania, 4
”Smart Lab Diagnostics” Timisoara, Romania, 5 Department of Microsurgery, “Victor Babes” University of Medicine
and Pharmacy, Timisoara, Romania